We help you challenge convention to accelerate and improve outcomes through optimized medical communications. Let’s work together.
With an entrepreneurial approach, we place innovation and excellence at the center of our dedicated practice areas in medical affairs and medical education for pharma and biotech.
Chronic disease management, oncology, specialized medicine, rare diseases, vaccines and infectious diseases, cell and gene therapies.
Combined expertise in understanding the patient experience, multi-disciplinary healthcare team working, poly-pharmacy and co-morbidities all underpinned with scientific rigor and expertise.
Experience and passion working in a fast-moving space – new targets, MOAs, and accelerated clinical development.
Vast experience in rare diseases, orphan drugs and gene therapies including working with small, innovative pharma and biotech.
VidERA: our custom-built vaccines and infective diseases offering combine our broad expertise across a plethora of infectious diseases, anti-infectives and vaccine solutions.
With our GenERA purpose-built cell and gene therapy offering, we are pioneers in this area with 300 years cumulative cell and gene therapy experience, and to date we have supported 137 therapies, across 58 technology platforms, through many key stages of the product lifecycle.
We stand at the forefront of innovation in medical affairs and medical education. We combine technology-forward solutions with our over 20 years long heritage in medical affairs and education to accelerate outcomes. We have delivered innovative medical affairs and medical education solutions for partners at all stages of asset and company development. Our current partnership list ranges from pre-commercial biotechnology firms to top 20 pharmaceutical companies.
Our innovative solutions are driven by insights, not just for the sake of innovation. They support your content to accelerate desired outcomes. Whether you are already embracing omnichannel or are actually not totally sure what it means, we can help!
Suzie Flowers, Principal Medical Writer at ApotheCom, explores the key differences between RNA and gene therapies and why clear terminology is crucial
Congresses are an excellent way to engage with oncologists, HCPs, and other key stakeholders.
Inizio Medical today proudly launches a new campaign that calls on the MedComms industry to do more to promote greater diversity in the sector.
Thinking about joining us?
Find out more about what it’s like to be working at ApotheCom.
